Investor Presentaiton

LOVVOLUS De JEUVEAU EXTRA-STRENGTH PHASE II DURATION STUDY EFFICACY: GLABELLAR LINE SCALE COMPOSITE SCORE NONE OR MILD AT MAXIMUM FROWN AND ≥ 2-POINT IMPROVEMENT Investigator + Subject Assessment (FDA Composite Score) PERCENT OF RESPONDERS 100 5 N WB · ŏ ∞ g 40 60 70 80 90 (%) 50 0 0 30 60 60 ◆No prabot data collected between Day 2 and Day 30 *DaxxifyⓇ FDA Prescribing Information (Graph GL1) Carruthers, Plastic Reconstructive Surgery 2020 Jan; 145 (1): 45-58 Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons Prabot 40U Phase II Daxi 40U Daxi 40U - Sakura 1 Sakura 2 90 120 150 180 210 240 270 DAYS AFTER TREATMENT 30 50

View entire presentation